Testosterone and Depression

Zarrouf, Fahd A.; Artz, Steven; Griffith, Jeffrey K.; Sirbu, Cristian; Kommor, Martin J.

doi:10.1097/01.pra.0000358315.88931.fc

Cited by 335 publications

(93 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This confirms the results of previous studies which showed that therapeutic interventions to address the endocrine dysfunction also help to ameliorate depression (16,17,19). A meta-analysis also confirms the positive effect of testosterone on depressed patients and in subpopulations with hypogonadism and HIV (20).…”

Section: Discussionsupporting

confidence: 78%

Depression Improvement Among Patients with HIV and Endocrine Dysfunction After hormone Therapy

Ghiasvand

Rahimi-Movaghar

Esteghamati

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Endocrine diseases, known as a curable etiology for depression, are common among men living with HIV (MLWH); while depression impedes the adherence to treatment and the perceived quality of life. We evaluated the changes in the depressive symptoms after the medical treatment of the underlying endocrine diseases among Iranian MLWH. Since April 2013 to March 2014, a convenience sample of 296 MLWH was recruited. We interviewed all the patients using the beck depression inventory (BDI-II) questionnaire.Participants with moderate to severe depression (n = 110, scores ≥ 21) were evaluated for endocrine diseases (evaluations: total testosterone, triiodothyronine, thyroxine, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, and serum cortisol). Eleven patients diagnosed with hypogonadism were, finally, considered for hormone replacement therapy. We re-evaluated the changes in the depressive symptoms with BDI-II. Out of 237 participants, 136 (75%) had BDI scores ≥ 21; 110 participated in the endocrine evaluations. Secondary hypogonadism was the only observed abnormality in 10% (n = 11) of the patients. Significant improvements were observed in BDI-II scores after 3 months of treatment (P = 0.027). The evaluation and the treatment of hypogonadism can help clinicians to properly address depression among people living with HIV; hence, improve the treatment compliance and the patient outcomes.

show abstract

Section: Discussionsupporting

confidence: 78%

Depression Improvement Among Patients with HIV and Endocrine Dysfunction After hormone Therapy

Ghiasvand

Rahimi-Movaghar

Esteghamati

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

show abstract

“…Although women produce less androgen hormone than men and metabolize a higher proportion of their androgen to oestrogen, direct androgen activity mediated via the AR influences development of the female phenotype and is important for the healthy functioning of multiple organs in women, including the ovaries (Lebbe & Woodruff 2013, O'Reilly et al 2014, Sen et al 2014, uterus (Wood et al 2009, Cloke & Christian 2012, bone (Watts et al 1995), muscle (Smith et al 2014), adipose tissue (Barbosa-Desongles et al 2013, Chazenbalk et al 2013, and brain (Shifren 2002, Lobo et al 2003, Ryan et al 2009, Zarrouf et al 2009). However, less is known about the mechanisms of AR signalling in female tissues compared with either AR signalling in male target tissues (e.g.…”

Section: Introductionmentioning

confidence: 99%

Bringing androgens up a NOTCH in breast cancer

Tarulli

Butler

Tilley

et al. 2014

Endocrine-Related Cancer

View full text Add to dashboard Cite

While it has been known for decades that androgen hormones influence normal breast development and breast carcinogenesis, the underlying mechanisms have only been recently elucidated. To date, most studies have focused on androgen action in breast cancer cell lines, yet these studies represent artificial systems that often do not faithfully replicate/ recapitulate the cellular, molecular and hormonal environments of breast tumours in vivo. It is critical to have a better understanding of how androgens act in the normal mammary gland as well as in in vivo systems that maintain a relevant tumour microenvironment to gain insights into the role of androgens in the modulation of breast cancer development. This in turn will facilitate application of androgen-modulation therapy in breast cancer. This is particularly relevant as current clinical trials focus on inhibiting androgen action as breast cancer therapy but, depending on the steroid receptor profile of the tumour, certain individuals may be better served by selectively stimulating androgen action. Androgen receptor (AR) protein is primarily expressed by the hormone-sensing compartment of normal breast epithelium, commonly referred to as oestrogen receptor alpha (ERa (ESR1))-positive breast epithelial cells, which also express progesterone receptors (PRs) and prolactin receptors and exert powerful developmental influences on adjacent breast epithelial cells. Recent lineage-tracing studies, particularly those focussed on NOTCH signalling, and genetic analysis of cancer risk in the normal breast highlight how signalling via the hormone-sensing compartment can influence normal breast development and breast cancer susceptibility. This provides an impetus to focus on the relationship between androgens, AR and NOTCH signalling and the crosstalk between ERa and PR signalling in the hormone-sensing component of breast epithelium in order to unravel the mechanisms behind the ability of androgens to modulate breast cancer initiation and growth.

show abstract

“…Но благоприятное дей-ствие на когнитивные функции, согласно результа-там исследований, было менее выраженным [74,75]. Следовательно, целесообразность проведения тера-пии тестостероном можно обсуждать после исклю-чения других причин когнитивных нарушений [76].…”

Section: благоприятные эффекты леченияunclassified

The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project

Дедов¹,

Мельниченко²,

Роживанов³

et al. 2015

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone which results in its low serum level in combination with characteristic clinical symptoms and/or signs (see the description below) that can be observed in the patients presenting with pathological changes in testicles and/or hypophysis, such as Kleinfelter’s syndrome, and in men with idiopathic metabolic or iatrogenic disorders leading to androgen deficiency. The present recommendations does not cover the entire set of pathological conditions responsible for the development of hypogonadism (deficit of testosterone); rather, they are focused on its clinical variants that account for the majority of the cases of male hypogonadism.

show abstract

Testosterone and Depression

Abstract: TT may have an antidepressant effect in depressed patients, especially those with hypogonadism or HIV/AIDS and elderly subpopulations. The route by which TT is administered may play a role in treatment response.

Cited by 335 publications

References 123 publications

Depression Improvement Among Patients with HIV and Endocrine Dysfunction After hormone Therapy

Depression Improvement Among Patients with HIV and Endocrine Dysfunction After hormone Therapy

Bringing androgens up a NOTCH in breast cancer

The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project

Contact Info

Product

Resources

About